# Acclarent

Type: Company

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/acclarent
Canonical HTML page: https://getfinancebrief.com/entity/acclarent

## Timeline

- **2026-02-26**: Q4 2025 Earnings — Company reports results and provides 2026 guidance, signaling continued remediation efforts.
- **2026 (estimated)**: Projected Restart — Target window for the commercial re-launch of SurgiMend and PriMatrix products.
- **2025-01-06**: New Leadership — Mojdeh Poul assumes role as CEO to lead the company's quality and operational turnaround.
- **2023-05-23**: Boston Recall — Integra initiates voluntary recall of all products manufactured in Boston due to endotoxin concerns.

## Recent coverage (1 stories)

### Integra LifeSciences Faces Market Pressure as Turnaround Timeline Extends
2026-02-26 22:45:09 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Integra LifeSciences (IART) shares faced downward pressure following its Q4 2025 earnings call, as management detailed an extended timeline for its Boston facility restart and the ongoing costs of its Quality Excellence Program. While the company provided its first full-year 2026 guidance, investor caution remains high regarding the path to normalized growth and product re-launches.
Full story: https://getfinancebrief.com/story/integra-lifesciences-iart-earnings-analysis-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.